BioXcel Therapeutics Inc expected to post a loss of $1.63 a share - Earnings Preview

BioXcel Therapeutics

01/08/2025 14:52

BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The New Haven Connecticut-based  company is expected to report a 76.9% decrease in revenue to $254.5 thousand from $1.1 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of $1.63 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $6.00, about 78.2% above its last closing price of $1.31

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-8.45
-6.66
-1.50
Beat
77.5
Dec. 31 2025
-6.04
-6.42
-3.57
Beat
44.4
Sep. 30 2024
-8.00
-8.67
-5.12
Beat
40.9​
Jun. 30 2024
-11.12
-11.36
-3.36
Beat
70.4
​​Mar. 31 2024
-10.25
-11.17
-13.92
Missed
-24.6
Dec. 31 2023
-15.12
-14.56
-12.16
Beat
16.5​
Sep. 30 2023
-21.50
-20.86
-27.52
Missed
-31.9
Jun. 30 2023
-28.83
-28.01
-29.28
Missed
-4.5

This summary was machine generated August 1 at 13:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)